Finch Therapeutics Group, Inc.
Finch Therapeutics Group, Inc. (FNCH) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · FNCH · as of Jun 30, 2024
Ownership Breakdown
1
Institutional Holders
▼ 9 vs Q1
$29,052
Total Inst. Value
▼ $309,156 vs Q1
1.61M
Shares Outstanding
freeFloat 55.81%
21,206
13F Shares Held
▼ 107,906 vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
FNCH largest shareholders · institutional ownership
Q2 2024 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
LAKE STREET ADVISORS GROUP, LLC biological products, (no diagnostic substances) | 21.2K | 1.32% | 1.32% | $29.05M | Aug 5, 2024 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 13, 2024 | EXIT |
MORGAN STANLEY biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | May 14, 2025 | EXIT |
BLACKROCK INC. biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 13, 2024 | EXIT |
SUSQUEHANNA INTERNATIONAL GROUP, LLP biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 15, 2024 | EXIT |
TOWER RESEARCH CAPITAL LLC (TRC) biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 13, 2024 | EXIT |
UBS GROUP AG biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 14, 2024 | EXIT |
IKARIAN CAPITAL, LLC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 14, 2024 | EXIT |
WELLS FARGO & COMPANY/MN biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 13, 2024 | EXIT |
BLEICHROEDER LP biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 13, 2024 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2024 vs prior quarter
Q2 2024
0
Increased
+0 shares0
New Positions
first time holders0
Decreased
−0 shares9
Sold Out
fully exitedNet shares change (top 50)
+0
+0 / −0
Net new holders
-9
0 new / 9 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
FNCH insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
2
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
SMISEK JEFFERY A director | Jun 7, 2024 | Gift | 383 | — | — | 24.4K | Form 4 ↗ |
SMISEK JEFFERY A director | Jun 7, 2024 | Gift | 384 | — | — | 17.9K | Form 4 ↗ |
SMISEK JEFFERY A director | May 20, 2024 | Gift | 3,750 | — | — | 0 | Form 4 ↗ |
SMISEK JEFFERY A director | Mar 28, 2024 | Sale | 1,600 | $2.61 | $4.2K | 6.5K | Form 4 ↗ |
SMISEK JEFFERY A director | Mar 28, 2024 | Sale | 6,642 | $2.57 | $17.1K | 0 | Form 4 ↗ |
SMISEK JEFFERY A director | Nov 22, 2023 | Sale | 1,470 | $3.64 | $5.4K | 6.6K | Form 4 ↗ |
Blischak Matthew P. Chief Executive Officer | Jun 9, 2023 | Award | 962,899 | $0.27 | $260.9K | 962.9K | Form 4 ↗ |
Blischak Matthew P. Chief Executive Officer | Jun 8, 2023 | Award | 962,899 | $0.28 | $274.4K | 962.9K | Form 4 ↗ |
Lange Christian H. director | Jun 8, 2023 | Award | 10,000 | $0.28 | $2.8K | 10.0K | Form 4 ↗ |
SMISEK JEFFERY A director | Jun 8, 2023 | Award | 10,000 | $0.28 | $2.8K | 10.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Finch Therapeutics Group, Inc. (FNCH) is primarily owned by institutional investors, who hold approximately 1.3% of total shares outstanding. Company insiders own approximately 44.19%, while retail and public investors account for the remaining 54.49%.
The largest institutional shareholder of Finch Therapeutics Group, Inc. is LAKE STREET ADVISORS GROUP, LLC, holding approximately 21,206 shares — equal to 1.32% of outstanding shares — as of June 30, 2024.
A total of 1 institutional investors currently hold FNCH stock, with a combined institutional value of approximately $29,052 as of the most recent 13F filing period.
Frequently asked questions
FNCH ownershipFinch Therapeutics Group, Inc. (FNCH) is primarily owned by institutional investors, who hold approximately 1.3% of shares. The largest shareholder is LAKE STREET ADVISORS GROUP, LLC with a 1.32% stake. Company insiders hold 44.19%. Data sourced from SEC Form 13F as of June 30, 2024.